Myomectomy Market Size
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 0.64 Billion |
| Market Size (2029) | USD 0.93 Billion |
| CAGR (2024 - 2029) | 8.10 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Myomectomy Market Analysis
The Myomectomy Market size is estimated at USD 0.64 billion in 2024, and is expected to reach USD 0.93 billion by 2029, growing at a CAGR of 8.10% during the forecast period (2024-2029).
An increase in the number of patients suffering from uterine fibroids is anticipated to be the key factor contributing to the growth of the myomectomy market. According to an article published by the International Journal of Reproduction, Contraception, Obstetrics, and Gynecology in July 2022, a study conducted in India showed that the incidence of fibroids was most common in 31-40 years of age, which was around 34.9%. The most commonly observed symptom for uterine fibroids was abdominal lump (41%) and abnormal uterine bleeding (24.1%). The prevalence of submucosal fibroids was 38.6%, intramural fibroids 19.3%, submucosal polyp 14.5%, seedling fibroid 13.9%, and subserosal fibroid 10.2%. Additionally, a rise in minimally invasive surgical procedures due to fewer complications and reduced hospital stays is anticipated to boost the market growth. Technological advancements such as the rise in robotic and laparoscopic-assisted surgeries to deliver quality and efficient treatment may also contribute to the growth of the myomectomy market.
According to an article published by MIS Journal in December 2022, uterine fibroids are considered a common benign smooth muscle tumor of the uterus that affects almost 70% of women until menopause. Risk factors of uterine fibroids include ethnicity, parity, early menarche, late menopause, family history, obesity, and hypertension. The presence of uterine fibroids is rarely life-threatening. However, they are often associated with symptoms affecting the quality of life, such as abnormal bleeding, pelvic pain, and urinary tract problems. The article also stated that robotic myomectomy has many advantages in uterine fibroid removal, such as lower blood loss, fewer complications, and shorter hospital stays over open surgery. The advantages of the wristed instruments, three-dimensional vision, and the incorporation of correct surgical techniques also emphasize the benefits of the robotic-assisted approach in large and numerous cases. Thus, the high burden of uterine fibroids and the increasing advantages of technologically advanced myomectomy procedures are expected to boost market growth.
The strategic activities by the market players, such as product launches and mergers and acquisitions, are expected to contribute to segmental growth over the forecast period. For instance, in November 2022, Olympus announced the launch of the moresolution Power Morcellator, manufactured by TROKAMED GmbH and available in the United States through a distribution agreement with Olympus America Inc. The moresolution Morcellator was designed for advanced gynecologic procedures with large, calcified tissue specimens. Olympus's Pneumoliner and the moresolution Morcellator can provide select patients with a laparoscopic surgical option.
Hence, factors such as the rising prevalence of uterine fibroids and the increasing advantages of technologically advanced myomectomy procedures are expected to boost market growth. However, the higher costs of new medical devices and complications associated with the procedure might restrict the growth of the market.
Myomectomy Market Trends
The Laparoscopic Segment is Expected to Hold a Significant Market Share over the Forecast Period
Laparoscopic myomectomy is a surgical procedure where the surgeon makes a small incision in or near the belly button. Then, a laparoscope is inserted into the abdomen; a laparoscope is a narrow tube fitted with a camera. Laparoscopic myomectomy has several advantages, such as less blood loss, shorter hospital stays, faster recovery, and lower complications and adhesion formation rates after surgery. Thus, the increasing advantages of laparoscopic myomectomy are expected to boost segmental growth. The increasing prevalence of uterine fibroids and the rising technological advancements in the laparoscopic myomectomy procedure are also expected to boost segmental growth.
According to an article published by PubMed Central in September 2022, laparoscopic myomectomy is one of the common procedures for uterine fibroid removal. Also, the article stated that a study showed that laparoscopic myomectomy combined with comprehensive rehabilitation nursing effectively reduced the postoperative stress state of patients with uterine fibroids, improved patient satisfaction, reduced adverse emotions, and promoted rehabilitation. Thus, the advantages of laparoscopic myomectomy are among the major factors driving segmental growth.
The rising prevalence of uterine fibroids is a major factor driving the market's growth. For instance, according to the data updated by the UK NHS in September 2022, uterine fibroids were common, with around two in three women developing at least one fibroid at some point in their life, and they most often occurred in women aged 30 to 50. Thus, the high prevalence of uterine fibroids is expected to boost the adoption of laparoscopic myomectomy during the forecast period. Moreover, the increasing research on urological diseases is expected to boost segmental growth during the forecast period.
Hence, factors such as the increasing advantages of laparoscopic myomectomy, the increasing research on urological diseases, and the rising prevalence of uterine fibroids are expected to enhance segmental growth over the forecast period.
North America is Expected to Hold a Significant Share in the Myomectomy Market Over the Forecast Period
North America is expected to hold a significant share of the myomectomy market over the forecast period due to the rising prevalence of uterine fibroid and technological advancements in myomectomy procedures.
Uterine fibroids are incredibly common, affecting many women by the age of 50. As the population ages, more women enter the age range where fibroids are most common, leading to a higher demand for treatment. For instance, in an article published by Elsevier Inc. in March 2022, in the United States, fibroids were referred to as the most common pelvic tumors in women of reproductive age, affecting 1 in 4 adult women. As per the same source, fibroids were the primary cause of hysterectomies in the United States and were the leading causes of hospitalizations for gynecologic conditions unrelated to pregnancy. Thus, the high burden of uterine fibroids in the United States is expected to boost market growth.
Furthermore, according to an article published by Taylor & Francis Online in December 2022, uterine fibroids (UF) were said to be noncancerous growths of the uterus and impact the livelihood of over 26 million women in the United States. Although UF may not have accompanying symptoms, their presence leads to surgical treatment for some women. Thus, the high prevalence of uterine fibroids is expected to boost market growth.
Hence, factors such as the rising prevalence of uterine fibroids are expected to enhance the market growth in the region over the forecast period.
Myomectomy Industry Overview
The myomectomy market remains highly competitive, with major players dominating the market. Technological advancements and product innovations will likely provide new opportunities for the players to compete within the market. The rise in laparoscopic and robotic-assisted myomectomy procedures due to their advantages over traditional methods may drive market growth. Some of the major market players include Medtronic PLC, Stryker Corporation, ConMed Corporation, INSIGHTEC Ltd, CooperSurgical Inc., Hologic Inc., KARL STORZ SE & Co. KG, B Braun, Richard Wolf Medical Instruments, and Minerva Surgical Inc.
Myomectomy Market Leaders
-
Medtronic PLC
-
ConMed Corporation
-
INSIGHTEC Ltd
-
CooperSurgical Inc.
-
Hologic Inc.
*Disclaimer: Major Players sorted in no particular order
Myomectomy Market News
- November 2023: Gynesonics unveiled an FDA-cleared medical device designed for both diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids. Uterine fibroids, a condition that impacts as many as 80% of adult women, can be addressed with this innovative technology.
- April 2022: Ethicon, part of Johnson & Johnson MedTech, launched the ENSEAL X1 Straight Jaw Tissue Sealer. The ENSEAL X1 Straight Jaw is indicated for use in open and laparoscopic general, gynecological, and urologic procedures.
Myomectomy Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Number of Patients Suffering from Uterine Fibroids
- 4.2.2 Rise in Minimally Invasive Procedures
- 4.2.3 Technological Advancements
-
4.3 Market Restraints
- 4.3.1 High Cost of Medical Devices
- 4.3.2 Complications Associated with the Procedure
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Buyers/Consumers
- 4.4.2 Bargaining Power of Suppliers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD)
-
5.1 By Type
- 5.1.1 Abdominal
- 5.1.2 Laparoscopic
- 5.1.3 Hysteroscopic
- 5.1.4 Robotic
-
5.2 By Product
- 5.2.1 Laparoscopic Power Morcellators
- 5.2.2 Harmonic Scalpel
- 5.2.3 Laparoscopic Sealer
- 5.2.4 Other Products
-
5.3 By End User
- 5.3.1 Clinics/Hospitals
- 5.3.2 Ambulatory Surgical Centers
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Rest of the World
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Medtronic PLC
- 6.1.2 Stryker Corporation
- 6.1.3 ConMed Corporation
- 6.1.4 INSIGHTEC Ltd
- 6.1.5 CooperSurgical Inc.
- 6.1.6 Hologic Inc.
- 6.1.7 Intuitive Surgical Inc.
- 6.1.8 KARL STORZ SE & Co. KG
- 6.1.9 B Braun SE
- 6.1.10 Richard Wolf Medical Instruments
- 6.1.11 Minerva Surgical Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityMyomectomy Industry Segmentation
Myomectomy is a surgical procedure to remove fibroids from the uterus. It allows the uterus to be left in place. It is for women who wish to get pregnant after receiving treatment for their fibroids. This procedure is considered the standard of care for removing fibroids and preserving the uterus.
The myomectomy market is segmented by type, product, end user, and geography. By type, the market is segmented into abdominal, laparoscopic, hysteroscopic, and robotic. By product, the market is segmented into laparoscopic power morcellators, harmonic scalpels, laparoscopic sealers, and others. By end user, the market is segmented into clinics/hospitals and ambulatory surgical centers. By geography, the market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for all the segments mentioned above.
| By Type | Abdominal | |
| Laparoscopic | ||
| Hysteroscopic | ||
| Robotic | ||
| By Product | Laparoscopic Power Morcellators | |
| Harmonic Scalpel | ||
| Laparoscopic Sealer | ||
| Other Products | ||
| By End User | Clinics/Hospitals | |
| Ambulatory Surgical Centers | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Rest of the World |
Myomectomy Market Research FAQs
How big is the Myomectomy Market?
The Myomectomy Market size is expected to reach USD 0.64 billion in 2024 and grow at a CAGR of 8.10% to reach USD 0.93 billion by 2029.
What is the current Myomectomy Market size?
In 2024, the Myomectomy Market size is expected to reach USD 0.64 billion.
Who are the key players in Myomectomy Market?
Medtronic PLC, ConMed Corporation, INSIGHTEC Ltd, CooperSurgical Inc. and Hologic Inc. are the major companies operating in the Myomectomy Market.
Which is the fastest growing region in Myomectomy Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Myomectomy Market?
In 2024, the North America accounts for the largest market share in Myomectomy Market.
What years does this Myomectomy Market cover, and what was the market size in 2023?
In 2023, the Myomectomy Market size was estimated at USD 0.59 billion. The report covers the Myomectomy Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Myomectomy Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Myomectomy Industry Report
Statistics for the 2024 Myomectomy market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Myomectomy analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
